Emerging Immunotherapy Combinations: What's Next in Lung Cancer Treatment?

Recent Trends in Combination Strategies

Over the past year, the focus in lung cancer immunotherapy has shifted from single-agent checkpoint inhibitors to rational combination regimens. Researchers are pairing PD-1/PD-L1 blockers with agents that target different immune checkpoints (e.g., CTLA-4, TIM-3, LAG-3) or with tumor microenvironment modulators such as anti-angiogenic therapies. Emerging data suggest that these combinations may overcome primary resistance and extend durable responses beyond what single agents achieve in first‑line and later‑line settings.

• Combinations with bispecific antibodies that engage two immune targets simultaneously are entering late‑stage trials.
• Adding low‑dose radiotherapy or personalized cancer vaccines to checkpoint inhibitors is being tested to prime a broader T‑cell response.
• Novel agents targeting STING agonists, TGF-β, and other immune‑regulatory pathways are being integrated into combination backbones.

Background: Why Combination Approaches Are Needed

Single‑agent immune checkpoint inhibitors have transformed treatment for non‑small cell lung cancer (NSCLC) but a large proportion of patients still do not respond or eventually relapse. Intrinsic immune evasion mechanisms—such as low tumor mutational burden, poor T‑cell infiltration, and immunosuppressive cytokines—limit the effectiveness of blocking PD‑1/PD‑L1 alone. Combining agents that act on complementary pathways aims to reignite an anti‑tumor immune cycle while circumparing resistance.

• Approximately one‑third of NSCLC patients respond to first‑line pembrolizumab, leaving a substantial unmet need.
• Acquired resistance often involves upregulation of alternative checkpoints (e.g., TIGIT, VISTA) or activation of oncogenic signaling.
• Combination trials have shown higher response rates in subgroups such as PD‑L1 high expressers and certain histologies (non‑squamous).

User Concerns: Practical Considerations for Patients and Clinicians

As combination regimens move closer to clinical practice, several common questions and concerns arise. Increased immune‑related adverse events are a primary worry—combinations may raise the rate of colitis, pneumonitis, and endocrinopathies. Treatment sequencing also matters; using two agents concurrently may affect options for later lines. Cost and access remain significant, especially for newer agents that may not yet have broad insurance coverage. Additionally, the lack of validated predictive biomarkers for many novel combinations makes patient selection uncertain.

• What is the real‑world toxicity profile compared to standard chemo‑immunotherapy?
• Will combination‑related side effects require more frequent monitoring or earlier steroid use?
• How should patients with autoimmune conditions or prior organ transplantation be considered for these trials?

Likely Impact on Clinical Practice

If ongoing large‑scale randomized trials confirm improved progression‑free and overall survival with manageable toxicity, combination immunotherapy is expected to expand first‑line options for both squamous and non‑squamous NSCLC. These regimens may also find roles in earlier stages (adjuvant/neoadjuvant) and in small cell lung cancer, where checkpoint inhibitors have shown modest benefit. However, the impact will depend on biomarker‑driven patient selection—those most likely to benefit could avoid ineffective combinations and unnecessary toxicity.

• Expected improvement in overall response rates in PD‑L1 low/negative populations.
• Possible reduction in the need for maintenance chemotherapy in some patient subgroups.
• Increased importance of molecular profiling (e.g., TMB, gene expression signatures, tumor‑infiltrating lymphocyte density) before choosing a combination.

What to Watch Next

Several key developments will shape the future landscape. Watch for results from phase III readouts of PD‑1 plus anti‑TIGIT combinations and bispecific antibodies targeting PD‑1 and VEGF. Biomarker validation studies that can separate responders from non‑responders will be crucial. Additionally, real‑world data registries and patient‑reported outcome studies will provide clarity on tolerability outside clinical trials. The next two to three years should clarify which combinations become standard and which patients are best suited for them.

• Regulatory decisions for at least two novel immuno‑combination regimens expected within the next year.
• Pooled analyses from multiple trials to identify consistent biomarker correlates of benefit.
• Emergence of sequential versus concurrent combination dosing schedules to balance efficacy and safety.